10-Q: United-Guardian Reports Q1 2025 Results: Sales Decline Driven by Cosmetic Ingredient Slowdown

United-Guardian's Q1 2025 net sales decreased by 24% year-over-year, primarily due to lower cosmetic ingredient sales, despite growth in pharmaceutical and medical lubricant segments.

Summary

• United-Guardian, Inc. reported a decrease in net sales for the first quarter of 2025, falling to $2,481,127 from $3,254,944 in the same period of 2024, representing a 24% decrease.
• The decline was primarily attributed to a significant decrease in sales of cosmetic ingredients, specifically the Lubrajel line, which was partially offset by increased sales in pharmaceutical and medical product lines.
• Cosmetic ingredient sales decreased by approximately 63%, with a notable reduction in purchases by Ashland Specialty Ingredients (ASI) by approximately 74%.
• ASI attributed the decrease to excess inventory in China and the timing of product orders, but confirmed no significant loss of business or customers.
• Pharmaceutical product sales increased by approximately 23%, from $950,323 in Q1 2024 to $1,168,458 in Q1 2025, driven by increased sales of Renacidin, which grew by approximately 38%.
• The increase in Renacidin sales was due to the resolution of production issues at the contract manufacturer's facility that had impacted Q1 2024 sales.
• Medical lubricant sales increased by approximately 43%, reaching $613,671 in Q1 2025 compared to $428,139 in Q1 2024, driven by increased orders from customers in India and China.
• Cost of sales as a percentage of net sales decreased to 45% in Q1 2025 from 48% in Q1 2024 due to a change in product mix.
• Operating expenses increased by approximately 11%, primarily due to increases in sales & marketing expenses and payroll and payroll related expenses.
• Research and Development (R&D) expenses increased by approximately 11%, mainly due to increased payroll and payroll-related expenses.
• Investment income decreased by approximately 14% due to lower interest income from United States Treasury Bills.
• Net income decreased from $925,442 to $560,895.
• Basic and diluted earnings per share decreased from $0.20 to $0.12.
• The company declared a cash dividend of $0.35 per share, paid on February 18, 2025.
• The company is monitoring the potential impact of tariffs, particularly those related to imports from China, on its business.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While there are positive aspects like increased sales in pharmaceuticals and medical lubricants, the overall decrease in net sales and net income, coupled with the risks associated with tariffs and customer concentration, balance out the positive elements.

Positives

• Pharmaceutical product sales increased by 23%, driven by a 38% increase in Renacidin sales.
• Medical lubricant sales increased by 43%, boosted by higher orders from customers in India and China.
• Cost of sales as a percentage of net sales decreased to 45% in Q1 2025 from 48% in Q1 2024.
• The company declared a cash dividend of $0.35 per share.

Negatives

• Net sales decreased by 24% year-over-year, primarily due to a decline in cosmetic ingredient sales.
• Cosmetic ingredient sales saw a significant decrease of 63%, largely due to reduced purchases by ASI.
• Investment income decreased by approximately 14% due to lower interest income from United States Treasury Bills.
• Net income decreased from $925,442 to $560,895.
• Basic and diluted earnings per share decreased from $0.20 to $0.12.

Risks

• The company faces global competition, particularly from Asian companies offering lower-priced alternatives.
• The company is monitoring the potential impact of tariffs, particularly those related to imports from China, on its business.
• A significant amount of cosmetic ingredient and medical lubricant sales are reliant on shipments to China.
• The company utilizes one contract manufacturer for the production of its pharmaceutical product, Renacidin, and any disruption in this manufacturer's operations could have a material impact on the company's revenue stream.
• Three pharmaceutical distributors and one cosmetic ingredient distributor collectively accounted for 67% of the company's gross sales and 67% of its outstanding accounts receivable.

Future Outlook

The company anticipates beginning manufacturing and revenue generation of its Natrajel line of sexual wellness ingredients in 2025. The company believes that its working capital is, and will continue to be, sufficient to support its operating requirements for at least the next twelve months. The company expects the Asian market to remain very competitive based on the continuing competition from lower-cost competitors, and for that reason we are concentrating our R&D efforts on developing new and unique products that other companies do not offer.

Management Comments

• ASI has confirmed that currently there has been no significant loss of business or customers.
• Our management team and Board of Directors are continuing to closely monitor our investment portfolio and have made and will continue to make any changes they believe may be necessary or appropriate to minimize the future impact on our financial position that the volatility of the global financial markets may have.

Industry Context

The company operates in the specialty chemicals and ingredients market, facing competition from both domestic and international players. The company's performance is influenced by global supply chain dynamics, trade policies, and the demand for its products in various sectors, including cosmetics, pharmaceuticals, and medical devices. The company's partnership with Brenntag Specialties reflects a strategic move to expand its presence in the sexual wellness market, aligning with the growing consumer interest in these products.

Comparison to Industry Standards

• United-Guardian's reliance on a few key distributors, particularly ASI, is a common practice in the specialty chemicals industry, where companies often leverage established distribution networks to reach a wider customer base.
• However, this concentration also poses a risk, as a significant change in the relationship with or performance of these distributors could materially impact the company's sales.
• Compared to larger, more diversified companies in the chemical sector like Ashland or Croda International, United-Guardian's revenue base is relatively small, making it more susceptible to fluctuations in demand for specific product lines or changes in market conditions.
• The company's focus on developing new and unique products through R&D aligns with industry trends, as companies seek to differentiate themselves and capture higher margins in competitive markets.
• The company's monitoring of trade policies and tariffs is also a standard practice in the industry, as these factors can significantly impact the cost competitiveness of products and access to key markets like China.

Related Party Transactions

• For the quarters ended March 31, 2025 and 2024, the Company paid PKF OConnor Davies $4,000 and $5,250 respectively, for accounting and tax services; Lawrence Maietta, a partner at PKF OConnor Davies, is a director of the Company.

Stakeholder Impact

• Shareholders will see a decrease in earnings per share and net income.
• Employees may be affected by changes in operating expenses and R&D spending.
• Customers in the cosmetic ingredient sector may experience supply chain disruptions due to decreased sales.
• Suppliers may be affected by changes in raw material purchases.
• Creditors may be affected by changes in working capital and the current ratio.

Next Steps

• The company anticipates beginning manufacturing and revenue generation of its Natrajel line of sexual wellness ingredients in 2025.
• The company is in the final stages of upgrading its building sprinkler system and expects the project to be completed during the second quarter of 2025.
• The company expects to continue to use its cash to make dividend payments, purchase marketable securities, and take advantage of growth opportunities that may arise that are in the best interest of the Company and its shareholders.

Key Dates

Keywords

sales, pharmaceuticals, cosmetic ingredients, medical lubricants, Renacidin, tariffs, ASI, dividends, financial results, Q1 2025